# Vamikibart in Participants With Uveitic Macular Edema

> **NCT05642325** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 256 (actual)

## Conditions studied

- Uveitic Macular Edema

## Interventions

- **DRUG:** Vamikibart
- **OTHER:** Sham

## Key facts

- **NCT ID:** NCT05642325
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-23
- **Primary completion:** 2025-05-07
- **Final completion:** 2025-12-24
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05642325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05642325, "Vamikibart in Participants With Uveitic Macular Edema". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05642325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*